In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat skin cancer. This week, we will be joined by Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA; Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy; Georgina Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia; and Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands.

We will hear on the impact of T-Cell therapies, such as lifileucel, in patients with melanoma; results of the 7-year CheckMate 238 trial (NCT02388906) of nivolumab; effective sequencing of treatments in the SECOMBIT trial (NCT02631447); and challenges in managing immunotherapy related adverse events.

If you would like to learn more about the recent approval of lifileucel by the FDA, you can find our feature article here. For other skin cancer news, be sure to visit our dedicated Skin Cancer Channel.

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.